Stock Scorer

Wave Life Sciences, Inc. (WVE)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. Every figure as a table ›

Revenue Quarterly

0 20M 40M 60M Q2 '20: 3M Q3 '20: 3.5M Q4 '20: 9.4M Q2 '21: 2.8M Q3 '21: 36.4M Q4 '21: 1.8M Q1 '22: 1.8M Q2 '22: 375K Q3 '22: 285K Q4 '22: 1.2M Q1 '23: 12.9M Q2 '23: 22.1M Q3 '23: 49.2M Q4 '23: 29.1M Q1 '24: 12.5M Q2 '24: 19.7M Q1 '25: 9.2M Q2 '25: 8.7M Q1 '26: 38.2M Q2 '26: 2.3M Q3 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q1 '25 Q2 '26

Operating Income Quarterly

-90M -60M -30M 0 30M 60M 90M Q3 '21: -7.6M Q4 '21: -36.1M Q1 '22: -38.1M Q2 '22: -42.2M Q3 '22: -38.9M Q4 '22: -43.6M Q1 '23: -30.3M Q2 '23: -23.5M Q3 '23: 4.4M Q4 '23: -18.7M Q1 '24: -34.5M Q2 '24: -35M Q3 '24: -63.9M Q4 '24: 23M Q1 '25: -49.8M Q2 '25: -52.8M Q3 '25: -56.4M Q4 '25: -56.5M Q1 '26: -31.3M Q2 '26: -73.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-75M -50M -25M 0 25M 50M 75M Q3 '21: -6.2M Q4 '21: -34.8M Q1 '22: -37.8M Q2 '22: -41.3M Q3 '22: -39M Q4 '22: -43.7M Q1 '23: -27.4M Q2 '23: -21.1M Q3 '23: 7.3M Q4 '23: -16.3M Q1 '24: -31.6M Q2 '24: -32.9M Q3 '24: -61.8M Q4 '24: 29.3M Q1 '25: -46.9M Q2 '25: -50.5M Q3 '25: -53.9M Q4 '25: -53.2M Q1 '26: -26.1M Q2 '26: -69.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-90M -60M -30M 0 30M 60M 90M Q3 '21: -28.2M Q4 '21: -7M Q1 '22: -39.9M Q2 '22: -28.8M Q3 '22: -25.6M Q4 '22: -33.4M Q1 '23: 85.5M Q2 '23: -37.3M Q3 '23: -34.5M Q4 '23: -33.2M Q1 '24: -33.4M Q2 '24: -27.5M Q3 '24: -46.5M Q4 '24: -43.6M Q1 '25: -63M Q2 '25: -46M Q3 '25: -44.7M Q4 '25: -33.8M Q1 '26: -59.6M Q2 '26: -53.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-90M -60M -30M 0 30M 60M 90M Q3 '21: -28.3M Q4 '21: -7M Q1 '22: -40.1M Q2 '22: -29.3M Q3 '22: -26.1M Q4 '22: -33.6M Q1 '23: 85M Q2 '23: -37.3M Q3 '23: -34.7M Q4 '23: -33.6M Q1 '24: -33.8M Q2 '24: -27.5M Q3 '24: -46.9M Q4 '24: -43.7M Q1 '25: -63.2M Q2 '25: -46.3M Q3 '25: -44.9M Q4 '25: -33.8M Q1 '26: -60M Q2 '26: -54.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 70M 140M 210M Q2 '21: 50M Q3 '21: 50.7M Q1 '22: 60.5M Q2 '22: 66.5M Q3 '22: 93.9M Q1 '23: 102.1M Q2 '23: 105.5M Q3 '23: 107M Q1 '24: 129.3M Q2 '24: 129.5M Q3 '24: 132.6M Q1 '25: 162.6M Q2 '25: 164M Q3 '25: 167.7M Q1 '26: 200.2M Q2 '26: 204M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-2.70 -1.80 -0.90 0.00 0.90 1.80 2.70 Q3 '21: -2.22 Q4 '21: -2.37 Q1 '22: -2.13 Q2 '22: -1.97 Q3 '22: -2.27 Q4 '22: -2.11 Q1 '23: -1.76 Q2 '23: -1.34 Q3 '23: -0.85 Q4 '23: -0.55 Q1 '24: -0.52 Q2 '24: -0.57 Q3 '24: -1.11 Q4 '24: -0.70 Q1 '25: -0.75 Q2 '25: -0.81 Q3 '25: -0.66 Q4 '25: -1.21 Q1 '26: -1.05 Q2 '26: -1.08 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

Not drawn for WVE: Gross Profit, Cost of Revenue. Nothing in this filer's XBRL supports them for the periods asked for. That is a gap in the filing, not a zero, and drawing a flat line would be an invention.